Source: Medthority

Alnylam: Alnylam's New Helios-B Data

Alnylam presents Phase III Helios-B study data on vutrisiran for ATTR-CM at ACC 2025.

Read full article »
Alnylam's Competitors | Alnylam's News | Alnylam's Financials
Stay up-to-date with the latest news on Alnylam
Annual Revenue
$1.0-5.0B
Employees
1.0-5.0K
John Maraganore's photo - CEO of Alnylam

CEO

John Maraganore

CEO Approval Rating

67/100

Read more
Stay up-to-date with the latest news on Alnylam